Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lung Non-Small Cell Squamous Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non Small Cell Lung Cancer (3690
)
Lung Adenocarcinoma (656
)
Lung Non-Squamous Non-Small Cell Cancer (163
)
Non Small Cell Lung Cancer (3690
)
Lung Adenocarcinoma (656
)
Lung Non-Squamous Non-Small Cell Cancer (163
)
›
Associations
(111)
News
Trials
Search handles
@GautschiOliver
@PatelOncology
@PatrickCMa1
@ShrutiPatelMD
@StephenVLiu
@diegoadiazg
Search handles
@GautschiOliver
@PatelOncology
@PatrickCMa1
@ShrutiPatelMD
@StephenVLiu
@diegoadiazg
Filter by
Latest
11ms
But don't forget about men too. My wife's best friend's never smoker husband presented with persistent dry cough😒 Dx w/ 7cm RML mass with supraclav node+😭 Squamous NSCLC, chemo refractory 😬 but... then found be ALK-fusion driven😁. Now in near-CR on Alectinib. 🙏🙏🙏🥂🏆😅✌️❤️ (@PatrickCMa1)
11 months ago
ALK fusion
|
Alecensa (alectinib)
12ms
Dr. Rafal Dziadziuszko discusses squamous NSCLC at #RomeLung23. Chemo-immunotherapy is effective - but clearly room for improvement. OSE2101 showing promise. Need for novel agents in this space. (@StephenVLiu)
12 months ago
Tedopi (OSE 2101)
1year
NEOTORCH included 90% men, 78% squamous NSCLC. This is a far cry from AEGEAN (46% squamous) and CheckMate 816 (49% squamous). Includes 67% stage IIIA and 32% stage IIIB. 66% were PDL1 positive (no breakdown on high vs low yet). #ASCOPlenarySeries (@StephenVLiu)
1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
1year
#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽CME Eval 🔗 https://t.co/I3w85MiXJq 👉🏽ALL🔗 https://t.co/jm2LDFMx5M 🤔@NarjustFlorezMD @ShrutiPatelMD taught us IO combos & irAEs, test your 🧠 What 1L IO in combo w chemo would U pick for met squamous NSCLC no action molecular bio & 37% PD-L1 (@ShrutiPatelMD)
1 year ago
PD-L1 (Programmed death ligand 1)
1year
Continued minimal durable benefit in PD-L1<1%-we need better approaches for this subgroup of squamous mNSCLC. whether utilizing aCTLA4 combinations or new targets (@PatelOncology)
1 year ago
PD-L1 (Programmed death ligand 1)
over1year
Here's the @DanaFarber squamous NGS experience led by @sands_jacob @lmsholl ⬇️. Once you find an EGFR / ALK / MET in a squamous NSCLC (I've seen each) it's hard to not test at least selectively. Don't need to delay tx, can use it to inform maintenance. https://t.co/Mna6RDrvrj (@geoff_oxnard)
over 1 year ago
Clinical • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor)
over1year
New potential targeted therapy for squamous NSCLC? TAK-228 (TORC1/2 inhibitor) in NRF2 activated NSCLC @JTOonline. In NFE2L2 mutant squamous NSCLC, RR 25% (3 out of 12) with impressive mPFS of 8.9m. Looking forward to larger studies. #LCSM https://t.co/wSSXfgCL8V (@StephenVLiu)
over 1 year ago
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
NFE2L2 mutation
|
sapanisertib (CB-228)
over1year
Jürgen Wolf discussing targets for squamous NSCLC including FGFR #ESMO22 @trnsltnl @nngmlungcancer (@GautschiOliver)
over 1 year ago
FGFR (Fibroblast Growth Factor Receptor)
over1year
SAKK 19/18 phase II study of rogaratinib in pts with squamous NSCLC expressing #FGFR mRNA now @LungCaJournal. Futility criteria met with only 1 pt reaching 6m PFS (mPFS 1.6m, mOS 3.5m). Toxicity included hyperphosphatemia, diarrhea, stomatitis. @Alfdoc2 https://t.co/FuKnKiDWyx (@StephenVLiu)
over 1 year ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
rogaratinib (BAY 1163877)
over2years
Love this. @n8pennell what's your approach for squamous given chance of METex14 and rare EGFR/ALK/etc? For small biopsies? Based on light smoking / Asian? Or worth doing for all squamous NSCLC? (@geoff_oxnard)
over 2 years ago
EGFR (Epidermal growth factor receptor)
over2years
For this 60 yo Asian M w stage IV squamous NSCLC metastatic to bone, NGS showed an EGFR exon 19 indel! 👏🎉 No TP53 or other prognostic alterations. PDL1 0%. Brain MRI w two 1cm brain mets, asymptomatic. How do you approach this case in clinic?? (@geoff_oxnard)
over 2 years ago
Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
almost3years
61y, female, stage IIIC (T3pN3) squamous NSCLC, partial response after concurrent CRT. NGS with BRAF V600E mut. What consolidation treatment would you offer? @AndresFCardonaZ @ogarrieta @n8pennell @dplanchard @VivekSubbiah @Jbauml @BenjaminBesseMD @peters_solange @StephenVLiu (@diegoadiazg)
almost 3 years ago
Clinical • Next-generation sequencing
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
3years
360 pts with advanced squamous NSCLC were randomized to carbo/pac + tislelizumab, carbo/nab-pac + tislelizumab or carbo/pac alone. PFS favored tislelizumab with either carbo/pac (7.6m, HR 0.52) or carbo/nab-pac (7.6m, HR 0.48) vs chemo alone (PFS 5.5m). Benefit across PDL1 strata (@StephenVLiu)
3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab)
3years
#WCLC20 Efficacy looks good including a lot of very durable responses - but note that this is an IO naive population and no word on PDL1 and outcomes. Still, mPFS in metastatic squamous NSCLC of 7.3m is encouraging. Not sure of development plan (IO naive vs exp, 1L/2L). #LCSM (@StephenVLiu)
3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login